Medidata RTSM vs Suvoda RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Medidata RTSM

Best for
Sponsors already on Rave EDC who want randomization and supply in the same system
What to consider
Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.
Read product profile

Suvoda RTSM

Best for
Oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
What to consider
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Medidata RTSM vs Suvoda RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureMedidata RTSMSuvoda RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Extended support

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source
About this support label

Named methods include permuted blocks and dynamic allocation with stratification.

Supported

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
About this support label

Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source
About this support label

Predictive supply schemes and forecasting are documented alongside direct-to-patient shipments.

Extended support

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
About this support label

Drug forecasting and direct-to-patient shipping are both named.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source
About this support label

A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.

Supported

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
About this support label

The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Supported

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source
About this support label

Rave and depot integrations establish base support; an API is not stated in this note.

Extended support

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
About this support label

Pre-built EDC API integrations and a REST API are stated.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source
About this support label

A certificate and audit are listed, but public document access is not established; trial statements require customer login.

Supported

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
About this support label

RTSM trial controls and an annual SOC audit are stated; public report access is not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
About this support label

Product-specific monthly patient usage is reported alongside a stated country count.

Extended support

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
About this support label

Product-specific trial adoption is reported across a stated country count.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.